Dated: November 26	2007	Sheet 1

FORM 1449*	
	INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION
(Use several sheets if necessary)

Docket Number: 12695.19USWO	Application Number: 10/549,505					
Applicant: Diakur et al.						
Filing Date: June 27, 2006	Group Art Unit: 1614					

		_	U.S. PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,282,778	11/1/1966	Lobel			
	6,043,259	3/28/2000	Dhalla et al.			
	6,051,587	04/18/2000	Dakashinamurti et al.			
	6,339,085 B1	01/15/2002	Haque			
	6,417,204 B1	07/09/2002	Haque			
	6,489,345	12/3/2002	Sethi			
	6,548,519 B1	04/15/2003	Haque			
	6,586,414	07/01/2003	Haque et al.			
	6,667,315 B2	12/23/2003	Haque			
	6,677,356	1/13/2004	Sethi et al.			
	6,780,997 B2	08/24/2004	Haque			
	6,861,439 B2	03/01/2005	Haque et al.			
	6,867,215 B2	03/15/2005	Haque			
	6,890,943 B2	05/10/2005	Haque			
	6,897,228 B2	05/24/2005	Haque			
	7,105,673 B2	09/12/2006	Haque			
	7,115,625 B2	10/03/2006	Sethi et al.			
	7,115,626 B2	10/03/2006	Sethi et al.			
	7,125,889 B2	10/24/2006	Sethi et al.			
	7,132,430 B2	11/07/2006	Sethi et al.			
	7,144,892 B2	12/05/2006	Sethi et al.			
	7,148,233 B2	12/12/2006	Sethi et al.			
	7,230,009 B2	06/12/2007	Haque et al.			
	2004/0121988 A1	06/24/2004	Haque et al.			
	2004/0171588 A1	09/02/2004	Haque			
	2004/0186077	09/23/2004	Diakur et al.			
	2004/0235907	11/25/2004	Sethi			
	2005/0107443 A1	05/19/2005	Haque			
	2006/0019929 A1	01/26/2006	Friesen			

EXAMINER		TE CONSIDERED	

Dated: November 26, 2007	Sheet 2 of 8			
FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 12695.19USWO	Application Number: 10/549,505		
IN AN APPLICATION	Applicant: Diakur et al.			
(Use several sheets if necessary)	Filing Date: June 27, 2006	Group Art Unit: 1614		

2006/0035864	02/16/2006	Friesen		
2006/0094748 AI	05/04/2006	Haque et al.		
2006/0094749 A1	05/04/2006	Haque et al.		
2006/0094761 A1	05/04/2006	Haque et al.		
2006/0148763 A1	07/06/2006	Friesen et al.		
2007/0032456	02/08/2007	Friesen		
2007/0060549	03/15/2007	Friesen		
2007/0142270 A1	06/21/2007	Haque et al.		
2007/0149485 A1	07/12/2007	Friesen		
2007/0167411 A1	07/19/2007	Reimer		
2007/0243249 A1	10/18/2007	Reimer		
2007/0249562 A1	10/25/2007	Reimer		
3,206,463	09/14/1965	Baetz		
3,910,921	10/07/1975	Esanu		
3,987,177	10/19/1976	Giudicelli et al.		
4,032,534	06/28/1977	Chodkiewicz		
4,036,844	07/19/1977	Thorne et al.		
4,053,607	10/11/1977	Thorne et al.		
4,137,316	01/30/1979	Esanu		
4,167,562	09/11/1979	Evers		
4,361,570	11/30/1982	Fici		
4,369,172	01/18/1983	Schor et al.		
4,374,841	02/22/1983	Descamps et al.		
4,515,771	05/07/1985	Fine		
4,567,179	01/28/1986	Lombardino		
4,569,938	02/11/1986	Esanu		
4,569,939	02/11/1986	Esanu		
4,581,363	04/08/1986	Esanu		
4,605,741	08/12/1986	Zagnoli et al.		
4,696,920	09/29/1987	Bentzen et al.		
4,730,042	03/08/1988	Hege et al.		
4,735,950	04/05/1988	Esanu		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in confor considered. Include copy of this form for next communication to the Applican	mance with MPEP 609; draw line through citation if not in conformance and not t.

Dated: November 26, 2007	Sheet 3 of 8		
FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 12695.19USWO	Application Number: 10/549,505	
IN AN APPLICATION	Applicant: Diakur et al.		

Filing Date: June 27, 2006

Group Art Unit: 1614

(Use several sheets if necessary)

4,735,956	08/05/1988	Baldwin et al.		
4,837,239	06/06/1989	Benjamin et al.		
4,843,071	06/27/1989	Hohenwarter		
4,962,121	10/09/1990	Hamberger et al.		
 5,001,115	03/19/1991	Sloan		
5,053,396	10/01/1991	Blass		
5,118,505	06/02/1992	Költringer		
5,130,324	07/14/1992	Ulrich et al.		
5,132,115	07/21/1992	Wolter et al.		
5,210,083	05/11/1993	Pfirrmann		
5,213,813	05/25/1993	Kornecki et al.		
5,254,557	10/19/1993	Buckle et al.		
5,254,572	10/19/1993	Serfontein		
5,272,165	12/21/1993	Ulrich et al.		
5,278,154	01/11/1994	Lacoste et al.		
5,288,716	02/22/1994	Speck		
5,326,757	07/05/1994	Demopoulos		-
5,328,453	07/12/1994	Sibalis		
5,372,999	12/13/1994	Schneider et al.		
5,385,937	01/31/1995	Stamler et al.		
5,420,112	05/30/1995	Lewis et al.		
5,441,972	08/15/1995	Ogata et al.		
5,504,090	04/02/1996	Neely		
5,563,126	10/08/1996	Allen et al.		
5,569,459	10/29/1996	Shlyankevich		
5,569,648	10/29/1996	Lewis et al.		
5,631,271	05/20/1997	Serfontein		
5,633,228	05/27/1997	Lewis et al.		
5,648,335	07/15/1997	Lewis et al.		
5,728,684	03/17/1998	Cheng et al.		
5,733,884	03/31/1998	Barbul et al.		
6 722 016	02/21/1000	Nb-		

	5,733,884	03/31/1998	Barbul et al.					
	5,733,916	03/31/1998	Neely					
EXAMINE	1			DATE CONSI	DERED			_
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.								

Dated: November 26, 2007	Sheet 4 of 8			
FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 12695.19USWO	Application Number: 10/549,505		
IN AN APPLICATION	Applicant: Diakur et al.			
a	Fill P 1 22 200/	0 4.00 5.000		

			.,			
5,770,215	06/23/1998	Moshyedi				
5,795,873	08/18/1998	Allen				
5,804,163	09/08/1998	Gibby et al.				
5,804,594	09/08/1998	Murad				
5,833,998	11/10/1998	Biedermann et al.				
5,834,446	11/10/1998	Dow et al.				
5,840,685	11/24/1998	Fujii et al.				
5,847,008	12/08/1998	Doebber et al.				
5,858,017	01/12/1999	Demopulos et al.				
5,859,051	01/12/1999	Adams et al.				
5,874,420	02/23/1999	Pelleg	]			
5,874,443	02/23/1999	Kiely et al.				
5,888,514	03/30/1999	Weisman				
5,944,020	08/31/1999	Markov et al.				
	F	DREIGN PATENT DOCUMEN	TS			
DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION
					YES	NO
831,350	01/14/1976	BE				х
863,754	05/29/1978	BÉ				х
561 183	04/30/1975	СН				х
1 958 226	05/27/1970	DE				
37 05 549 A1	09/01/1988	DE			-	
43 44 751 A1	06/29/1995	DE				х
24 61 742 A	07/08/1976	DT				х
0 121 036 A1	10/10/1984	EP				
0 144 051 A2	06/12/1985	EP				
0 270 026 A2	06/08/1988	EP				
0 416 248 A2	03/13/1991	EP				
0 891 719 AI	01/20/1999	EP				
846,376	03/26/1941	FR				
						+
1,323,941	12/15/1963	FR				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form for next communication to the Applicant.	

Dated: November 26, 2007	Sheet 5 o

FORM 1449\*
INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

12695.19USWO
Applicant: Diakur et al.

Docket Number:

10/549,505

Application Number:

(Use several sheets if necessary)

Filing Date: June 27, 2006 Group Art Unit: 1614

5,801 M	03/28/1968	FR			
6,453 M	12/16/1968	FR			x
1,579,544	08/29/1969	FR			
2,034,539	12/11/1970	FR			
2,101,010	03/31/1972	FR			x
2,255,883	07/25/1975	FR			х
2,428,640	01/11/1980	FR			x
1 013 939	12/22/1965	GB			
I 172 800	12/03/1969	GB			
1 201 014	08/05/1970	GB			
1 297 080	11/22/1972	GB			
1 360 536	07/17/1974	GB			
1 493 993	12/07/1977	GB			
2 254 556 A	10/14/1992	GB			
48-21959	07/02/1973	JP			х
54-17130	02/08/1979	JP			х
10-158244	06/16/1998	JP		Abstract	
2000-26295	01/25/2000	JP		Abstract	
WO 83/00085	01/20/1983	PCT			
 WO 91/19500	12/26/1991	PCT		Abstract	
WO 94/18965	09/01/1994	PCT			
WO 96/12487	05/1996	PCT			
WO 98/28310	07/02/1998	PCT			
WO 99/03365	01/28/1999	PCT			
WO 99/53928	10/28/1999	PCT			
WO 2005/060975	07/07/2005	PCT			
WO 2006/005173	01/19/2006	PCT			
WO 2006/026868	03/16/2006	PCT			
WO 2006/056079	06/01/2006	PCT			
WO 2006/058411	06/08/2006	PCT			
WO 2006/102748	10/05/2006	PCT			
WO 2006/136004	12/28/2006	PCT			

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Dated: November 26, 2007		Sheet 6 of 8		
FORM 1449*	Docket Number:	Application Number:		

| 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/549.505 | 10/

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Arbuzov, S., "Pharmacologocial Properties of the Products of the Condensation of Phenamine with Some Metabolites", Farmakol. Toksikol, Vol. 31, No. 3, pp. 373-376 (1968) (Abstract only).
Arbuzov., S., "Synthesis and Pharmacological Investigation of Some New Compounds Related Structurally to Some Natural Metabolites", Conf. Hug. Ther. Invest. Pharmacol., Soc. Pharmacol. Hung., 489-502 (1966) (Abstract only)
Aybak, M. et al., "Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension", Drug Res., Vol. 45, No. 12, pp. 1271-1273 (1995).
"B Vitamins May Cut Heart Disease Risk", Harvard Health Letter", 1 page (1998)
Baliga, B. et al., "Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine", Endocrine Practice, Vol. 6, No. 6, pp. 435-441 (November/December 2000).
Barrett, S., "Homocysteine: A Cardiovascular Risk Factor Worth Considering", http://www.quackwatch.com/03HealthPromotion/homocysteine.html, 2 pages (©1997)
Bennett, R. et al., "Vitamin B <sub>5</sub> -Phosphonic Acids", Journal of Medicinal and Pharmaceutical Chemistry, Vol. 1, No. 3, pp. 213-221 (1959).
Bernstein, A., "Vitamin B <sub>6</sub> in Clinical Neurology", Annals of New York Academy of Sciences, Vol. 585, pp. 250-260 (1990)
Berger, A.R. et al., "Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity", Neurology, Vol. 42, No. 7, pp. 1367-1370 (July 1992)
Bhagavan, H. et al., "Effect of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats", Pediat. Res., Vol. 10, pp. 730-732 (1976).
Bode, W. et al., "Pyridoxal-5'-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6", J. Nutr., Vol. 121, No. 11, pp. 1738-1745 (November 1991)
Bundgaard, Design and Application of Prodrugs in A Textbook of Drug Design and Development (Krogsgaard-Larson & Bundgaard, eds., Hardwood Academic Publishers, Reading, United Kingdom (1991)
Chasan-Taber, L. et al., "A Prospective Study of Folate and Vitamin B <sub>6</sub> and Risk of Myocardial Infarction in US Physicians", Journal of the American College of Nutrition, Vol. 15, No. 2, pp. 136-143 (April 1996)
Cho, Y. et al., "In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis", J. Nutr., Vol. 120, pp. 258-265 (1990)
"Computer Generated Search Reports", 70 pages (May 1999)
Ebudi, M. et al., "Convulsant Activity of Pyridoxal Sulphate and Phosphonoethyl Pyridoxal: Antagonism by GABA and its Synthetic Analogues", Neuropharmacology, Vol. 22, No. 7, pp. 865-873 (1983)
Ellis, J. et al., "Prevention of Myocardial Infarction by Vitamin B <sub>6</sub> ", Res. Commun. Molec. Pathol. Pharmacol., Vol. 89, No. 2, pp. 208-220 (August 1995)
Folsom, A. et al., "Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study", Crivaliator, Vol. 98, pp. 201-210 (Usy 21, 1998).
Fonda, M., "Interaction of Pyridoxal Analogues with Glutamate Apodecarboxylase and Aspartate Apoaminotrans ferase", The Journal of Biological Chemistry, Vol. 246, No. 7, pp. 2230-2240 (1971)
Harada, K. et al., "Studies on Vitamin B <sub>6</sub> . (IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration", Vitamins Journal of the Vitamin Society of Japan, Vol. 45, No. 2, pp. 69-75 (February 1972)
Hathcock, J., "Vitamins and minerals: efficacy and safety", Am J Clin Nutr, Vol. 66, pp. 427 - 437 (1997)
Hoover, D.M. et al., "Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs", Vet. Pathol., Vol. 18, pp. 769-777 (1981)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in confor considered. Include copy of this form for next communication to the Applicant.	

Dated: November 26, 2007	Sheet 7 of 8			
FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 12695.19USWO	Application Number: 0/549,505		
IN AN APPLICATION	Applicant: Diakur et al.			
(Use several sheets if necessary)	Filing Date: June 27, 2006	Group Art Unit: 1614		

Kim, Y. et al., "Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylazo-5'-phosphate and Phosphonate Derivatives as P2 Receptor Antagonists", Drug Development Research, Vol. 45, pp. 52-66 (1998)
Kok, F. et al., "Low Vitamin B6 Status in Patients with Acute Myocardial Infarction", Am. J. Cardiol., Vol., 63, pp. 513-516 (March 1, 1989)
Korytnyk, W., "Pyridoxine Chemistry. VI. Homologs of Pyridoxol and of 5-Pyridoxic Acid", Dept. of Exp. Therapeutics, Roswell Park Memorial Institute, Buffalo. New York, Vol 8, pp. 112-115 (1965)
Korytnyk, W. et al., "Synthesis and Antagonist Properties of Pyridoxol Analogs Modified in the 5 Position", Pyridoxal Analogs, Dept. of Exp. Therapeutics, Roswell Park Memorial Institute, Buffalo, New York, Vol. 10, pp. 345-350 (May 1967)
Korytnyk et al., "Schiff Bases of Pyriodoxal: Their Structure and the Stabilization of their Ring-Chain Tautomeric Forms by Acylation, Tetrahedron, 26 (23), 5415-5425 (1970)
Korytnyk et al., "Selective Modifications of the 4-Position of Pyridoxol. I. Extension and branching of the 4-side Chain", Dept. of Exp. Therapeutics, Roswell Park Memorial Institute, Buffalo, New York, Vol. 13, pp. 187-191 (March 1970)
Krinke, G. et al., "Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B <sub>6</sub> in Rat Primary Sensory Neurons", J. Neuropathol. Exp. Neurol., Vol. 44, No. 7, pp. 117-129 (March 1985)
Kubyshkin, V. et al., "Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correction in dilated and hypertrophic cardiomyopathy", Ter. Arkh. 61(9): 82-85 (1989).
Lai, K. et al., "Hypotensive action of 5-HT receptor agenists in the vitamin B <sub>0</sub> -deficient hypertensive rat", Eur. J. Pharmacol., Vol. 234, Nos. 2/3, pp. 183-189 (April 1993)
Lat, K. et al., "Calcium channels in vitamin B <sub>4</sub> deficiency-induced hypertension", <i>Journal of Hypertension</i> , Vol. 11, No. 12, pp. 1357-1362 (December 1993)
Lal, K. et al., "The effect of vitamin B <sub>6</sub> on the systolic blood pressure of rats in various animal models of hypertension", <i>Journal of Hypertension</i> , Vol. 14, No. 3, pp. 355-363 (March 1996)
Levy, H. et al., "Pyridoxine Deficiency in Congestive Heart Failure", P.S.E.B.M., Vol. 101, pp. 617-621 (1959)
Manore, M. et al., "Changes In Plasma Pyridoxal Phosphate (PLP) In Diabetic (D), Hypertensive (HTN) and Hypertensive-diabetic (HTN-D) Men Fed A Constant Vitamin B-6 (B6) Diet", FASEB J., Abstract 1254 (1991).
Markov, A. et al, "Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia",  **American Heart Journal, Vol. 100, No. 5, pp. 639 - 646 (November 1980)
Mendelsohn, A. et al., "Hemodynamic and Clinical Effects of Oral Levodopa in Children With Congestive Heart Failure", JACC, Vol. 30, No. 1, pp. 237-242 (July 1997).
Merrill, Jr. et al. A. et al., "Diseases associated with defects in vitamin B <sub>6</sub> metabolism or utilization", Ann. Rev. Nutr., Vol. 7, pp. 137-156 (1987)
Miura, R. et al., "Reactions of Phosphonate Analogs of Pyridoxal Phosphate with Apo-asparate Aminotransferase", Archives of Biochemistry and Biophysics, Vol. 270, N. 2, pp. 526-540 (1989)
Mulvaney, D. et al., "Electrocardiographic changes in vitamin B <sub>6</sub> deficient rats", Cardiovascular Research, Vol. 13, pp. 506-513 (1979).
Omenn, G. et al., "Preventing Coronary Heart Disease", Circulation, Vol. 97, pp. 421-424 (1998)
Paulose, C. et al., "Sympathetic Stimulation and Hypertension in the Pyridoxine-Deficient Adult Rat", Hypertension, Vol. 11, No. 4, pp. 387-391 (April 1988)
Rao, R. et al., "Failure of Pyridoxine to Improve Glucose Tolerance in Diabetics", Journal of Clinical Endocrinology & Metabolism, Vol. 50, No. 1, pp. 198-200 (January 1980).
Rumm, E. et al., "Folate and Vitamin Be From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women", JAMA, Vol. 279, No. 5, pp. 359-364 (February 4, 1998)

No. 5, pp. 359-364 (February 4, 199	8)
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether of considered. Include copy of this form for next commit	or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not unication to the Applicant.

Dated: November 26, 2007	Sheet 8 of 8			
FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 12695.19USWO	Application Number: 10/549,505		
IN AN APPLICATION	Applicant: Diakur et al.			
(Use several sheets if necessary)	Filing Date: June 27, 2006	Group Art Unit: 1614		

	Sakuragi, T. et al., "The Synthesis of Long Chain Fatty Acid Derivatives of the Vitamin B <sub>6</sub> Group", J. Am. Chem. Soc., Vol. 78, pp. 839-842 (February 20, 1956)
	Sethi, R. et al., "Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure", The American Physiological Society, Vol. 272, No. 2, Part 2 of Two Parts, pp. H884 - H893 (February 1997)
	Sethi, R. et al., "Inotropic Responses to Isoproterenol in Congestive Heart Failure Subsequent to Myocardial Infarction in Rats",  Journal of Cardiac Failure, Vol. 1, No. 5, pp. 391 - 399 (December 1995)
	Stirtan, W. et al., "Phosphonate and Fluorophosphonate Analogue Probes of the Ionization State of Pyridoxal 5'-Phosphate (PLP) in Glycogen Phosphorylase", Biochemistry, Vol. 35, No. 47, pp. 15057-15064 (1996)
	Takuma, Y. et al., "Combination Therapy of Infantile Spasms With High-Dose Pyridoxal Phosphate and Low-Dose Corticotropin", Journal of Child Neurology, Vol. 11, No. 1, pp. 35-40 (January 1996).
	Tanaka, T. et al., "Pyridoxine Derivatives", Chemical Abstracts, Vol. 62, No. 12, 1 page (June 7, 1965)
	Tomita, I. et al., "SYnthesis of Vitamin B <sub>2</sub> Derivatives. II 3-Hydroxy-4-Hydroxymethyl-2-Methyl-5-Pyridine Acetic Acid and Related Substances", Dept. of Blochem. and Biophys., Iowa State Univ., Vol. 3, pp. 178-183 (1996)
	Trezise, D. et al., "P2 purinoceptor antagonist properties of pyridoxal-5-phosphate", Eur. J. Pharmacol., Vol. 259, No. 3, pp. 295-300 (July 11, 1994)
	Vanderjagt, D. et al., "Vitamin B <sub>6</sub> Status in a Healthy Elderly Population", Annals New York Academy of Sciences, pp. 562 - 564 (date unknown)
	Verhoef, P. et al., "A Common Mutation in the Methylenetetrahydrofolate Reductase Gene and Risk of Coronay Heart Disease: Results Among U.S. Men,", JACC, Vo. 32, No. 2, pp. 353-359 (August 1998)
	Verhoef, P. et al., "Homocysteine Metabolism and Risk of Myocardial Infarction: Relation with Vitamins B <sub>6</sub> , B <sub>13</sub> , and Folate", Am. J. Epidemiol., Vol. 143, No. 9, pp. 845-859 (May 1, 1996)
	Vermaak, W.J.H. et al., "Vitamin B <sub>6</sub> and coronary artery disease. Epidemiological observations and case studies", <i>Atherosclerosis</i> , Vol. 63, pp. 235-238 (February 1987)
	Vidrio, H., "Interaction with Pyridoxal as a Possible Mechanism of Hydralazine Hypotension", Journal of Cardiovascular Pharmacology, Vol. 15, pp. 150-156 (1990).
	Viscontini, V. et al., "Über einige Derivate des Pyridoxals", Helvetica Chimica Acta, Vol. 34, No. 296, pp. 2438-2439 (1951)
	Windebank, A., "Neurotoxicity of Pyridoxine Analogs Is Related to Coenzyme Structure", Neurochemical Pathology, Vol. 3, pp. 159-167 (1985)
	Yan, S. et al., "A Role for Pyridoxal Phosphate in the Control of Dephosphorylation of Phosphorylase d", J. of Biological Chem., Vol. 254, No. 17, pp. 8263-8269 (1979)
	Yarat, A. et al., "Effect of vitamin B6 on lenses of diabetic rats", Indian Journal of Experimental Biology, Vol. 36, pp. 1269-1272 (December 1998)
	Zempleni, J. et al., "The utilization of intravenously infused pyridoxine in humans", Clinica Chimica Acta, Vol. 229, Nos. 1, 2, pp. 27-36 (September 1994)

EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.